MARKET WIREYahoo! Finance Canada • 21h ago
Bio-Rad Laboratories, Inc. (BIO) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
Why BIO Stock slipped -1.62% Today — RQD Quant Desk Flash
$366.16 -1.62% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $364.40
Bio-Rad Laboratories Inc. (BIO) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $9.95B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BIO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Bio-Rad Laboratories Inc. (NYSE: BIO) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $366.16 (-1.62% 1D, market cap $9.95B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 14/20. Across 1015 tracked Health Care issuers, BIO ranks #146 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BIO compare to TXG and AVTR in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), BIO carries a Roarable C (62/100 RQD), trailing P/E of 13.5x, gross margin of 51.9%, and ROIC of 0.5%. By comparison, TXG (10x Genomics Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC -5.7%, cap $9.13B) and AVTR (Avantor Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC -2.1%, cap $10.88B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BIO?
▼
Per BIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000012208), Bio-Rad Laboratories Inc. generated $2.58B in revenue (+0.7% YoY), $759.9M in net income, and $374.6M in free cash flow against $10.58B in total assets and $1.20B in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $364.40 (-0.48%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 14.5% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BIO)Realized 20D OHLCV Swing Band: ±6.2%
Deterministic 5-Pillar Attribution (62/100 Composite)
🔍 WHY BIO SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (26% of score)
Altman Z-Score 3.59 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+14/20 pts (23% of score)
SEC Form 4 / 13F Thermometer: 70% Net Buy • Cannibal Buyback (-1.80% YoY Shares)
▼ #1 Drag / Risk Factor: Cash Engine Quality7/20 pts (-13 pt drag)
Capital intensity & 1.8% operating margin leave 13 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$362.43-0.5% Next Q
54
Q2 (-2Q)Grade C$360.50+6.8% Next Q
57
Q3 (-1Q)Grade C$385.12-4.9% Next Q
59
CurrentGrade C$366.16+0.7% Hist 90D α
62
Trajectory: C- (54) → C (62)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the BIO Bull Thesis Could Fail
Even with a 62/100 (C) score, BIO faces multiple-compression risk if 13.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 49.4% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($374.58) or 200D SMA ($314.37) invalidates the momentum regime and cuts Target Base ($372.75) toward Bear Floor ($290.75).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BIO Stock slipped -1.62% Today — RQD Quant Desk Flash
Bio-Rad Laboratories Inc. (BIO) slipped -1.62% to $366.16, trading at 81% of its 52-week range ($236.73 – $396.23). Solid 51.9% gross margin (1% return on capital), mixed timing at 14x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 81% of its 52-week range ($236.73 – $396.23) with RSI-14 at 50.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.2% around $366.16 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 51.9% gross margin and $374.6M annual free cash flow.
Live BIO Headlines & Catalysts
MARKET WIREYahoo Finance Singapore • 1d ago
Bio-Rad Laboratories, Inc. (BIO) stock price, news, quote and historyYahoo Finance Singapore report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 1d ago
Bio-Rad Laboratories Inc (BIO) Stock Down 3.0% but Still OvervalGuruFocus report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
How Investors Are Reacting To Bio Rad Laboratories Stock Vericheck Kit ExpansionSimply Wall St report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A 2 p.m. Pacific call is scheduled to discuss Bio-Rad's third-quarter results Nov. 4.Stock Titan report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Bio-Rad Laboratories (NYSE:BIO) Stock Forecast & Analyst PredictionsSimply Wall St report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
With awards vesting 25% yearly, Bio-Rad (BIO) COO acquires 1,869 shares.Stock Titan report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo Finance • 1d ago
Bio Rad Laboratories (BIO) Stock Dropped, What Is Behind The Fresh Attention?Yahoo Finance report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 21h ago
Flow Cytometry Products and Services - Global Strategic Business Report: Capitalize on $1.7B Growth to $6.4B by 2030 as Thermo Fisher, Becton Dickinson, Beckman Coulter and Bio-Rad Battle for ShareOptimize ROI with segment, regional, competitive and tariff insights that sharpen sourcing, market positioning and revenue strategies.Dublin, Nov. 02, 2026 (GLOBE NEWSWIRE) -- "Flow Cytometry Products and Services - Glob
CATALYSTYahoo • 21h ago
Biotechnology Reagents - Global Strategic Business Report: Capture the US$60.7 Billion Market by 2032 as Thermo Fisher, Roche, Danaher, Merck, and Bio-Rad Drive DisruptionR&D investment, CRISPR, NGS, personalized medicine and diagnostics drive demand, while strategic partnerships accelerate reagent innovation and commercialization.Dublin, Nov. 02, 2026 (GLOBE NEWSWIRE) -- "Biotechnology R
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (BIO Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +42.00%🛡️ HOLDING TREND SUPPORT
2026-11-03O $384.4H $384.4L $366.2C $366.2VOL 183.1K
RES: $389.6SUP: $356.6SMA50: $374.6SMA200: $314.4
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
5.0%/yr Implied 5Y Growth
vs. +0.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on BIO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BIO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BIO)
Health Care Rank #146 of 1015
⚔️ TXG vs BIO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BIO vs. TXG, AVTR, BRKR, RVTY)
Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Bio-Rad Laboratories Inc. (BIO) ranks #146 by composite RQD confidence (62/100, grade C) and #110 by equity capitalization ($9.95B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while RVTY leads on capital efficiency and profitability with 3.1% ROIC and — gross margin. RVTY currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with BIO at 62/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BIO
ACTIVE
Bio-Rad Laboratories Inc. | C | 62/100 | 13.5x | 51.9% | 0.5% | -1.62% | $9.95B | Benchmark Subject |
| TXG 10x Genomics Inc. | C- | 59/100 | — | 69.1% | -5.7% | -12.09% | $9.13B | /txg-vs-bio → |
| AVTR Avantor Inc. | D+ | 56/100 | — | 32.7% | -2.1% | -2.74% | $10.88B | /avtr-vs-bio → |
| BRKR Bruker Corporation | D+ | 54/100 | — | 45.9% | 1.3% | -2.42% | $8.70B | /brkr-vs-bio → |
| RVTY Revvity Inc. | C | 65/100 | 76.7x | — | 3.1% | -3.44% | $17.52B | /rvty-vs-bio → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000012208 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bio-Rad Laboratories Inc. (BIO) reported GAAP revenue of $2.58B (+0.7% vs. FY2024 revenue of $2.57B , and -3.3% cumulative change since FY2023) , GAAP net income of $759.9M, operating cash flow of $532.2M, and free cash flow of $374.6M (+29.4% YoY). On the balance sheet, BIO closed FY2025 with $10.58B in total assets against $1.20B in total debt (Altman Z-Score: 3.59, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.58B | $759.9M | $532.2M | $374.6M | $10.58B | $1.20B |
| FY2024 (FY) | 2024-12-31 | $2.57B | -$1.84B | $455.2M | $289.6M | $9.36B | $1.20B |
| FY2023 (FY) | 2023-12-31 | $2.67B | -$637.3M | $374.9M | $254.7M | $5.65B | $1.32B |
3. BIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Bio-Rad Laboratories Inc. (NYSE: BIO) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $366.16 (-1.62% 1D, market cap $9.95B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 14/20. Across 1015 tracked Health Care issuers, BIO ranks #146 in composite RQD confidence.
How does BIO compare to TXG and AVTR in the Health Care sector?
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), BIO carries a Roarable C (62/100 RQD), trailing P/E of 13.5x, gross margin of 51.9%, and ROIC of 0.5%. By comparison, TXG (10x Genomics Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC -5.7%, cap $9.13B) and AVTR (Avantor Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC -2.1%, cap $10.88B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BIO?
Per BIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000012208), Bio-Rad Laboratories Inc. generated $2.58B in revenue (+0.7% YoY), $759.9M in net income, and $374.6M in free cash flow against $10.58B in total assets and $1.20B in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BIO trading relative to its 50-day, 200-day, and 52-week technical levels?
BIO last traded at $366.16 (-1.62% on volume of 211,900 shares), positioning the stock -2.25% below its 50-day simple moving average ($374.58) and +16.47% above its 200-day simple moving average ($314.37). Across its 52-week range of $236.73 to $396.23, BIO sits at the 81.1% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±6.2% ($343.46 to $388.86).
ROARABLE RATING BRIEF • RQD 62/100 (C)
✓ SEC XBRL & RQD VERIFIED
BIO — Bio-Rad Laboratories Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Bio-Rad Laboratories Inc. (BIO) earns a live Roarable RQD composite score of 62/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $366.16 (-1.62% 1D, market capitalization $9.95B).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of 0.5%, gross margin of 51.9%, operating margin of 1.8%, and free cash flow yield of 3.64%.
- Whale 13F & Options Flow (13/20) + Insider Conviction (14/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (12/20) + Forensic Balance Sheet (16/20): Incorporates a 1.04x equity beta, Altman Z-Score of 3.59, Piotroski F-Score of 7/9, and Debt/Equity of 0.16x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Bio-Rad Laboratories Inc. (BIO) is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry. The source data identifies the company's market capitalization as $10.3B. Revenue is reported in the SEC financials at $2.58B for FY 2025.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Bio-Rad Laboratories Inc. (BIO) reported $2.58B in annual revenue (up from $2.57B in FY2024, +0.7% YoY) and $759.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.67B revenue, -$637.3M net income) through FY2025, BIO scaled operating cash flow to $532.2M and free cash flow to $374.6M, backed by $10.58B in total assets against $1.20B in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (C • RQD 62/100): Company leadership has skin in the game with net positive insider conviction. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $236.73 – $396.23 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 13.5x trailing P/E and 60.4x EV/EBITDA against 1.8% operating margins and a 1.04x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The only sector context provided is Health Care / Biotechnology: Laboratory Analytical Instruments, and the beta of 1.04 per the market data. An investor should not infer specific supplier or customer ripple effects from the source material.
- Key Question #1: Can BIO sustain or expand its 1.8% operating margin and 0.5% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $2.58B and free cash flow of $374.6M, how will capital allocation balance growth reinvestment against $1.20B in total debt?
- Key Question #3: How sensitive is BIO's 12.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.04x)?
BIO Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Bio-Rad Laboratories Inc. (BIO) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 21h ago
Bio-Rad Laboratories, Inc. (BIO) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Singapore • 1d ago
Bio-Rad Laboratories, Inc. (BIO) stock price, news, quote and history Yahoo Finance Singapore report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
Bio-Rad Laboratories Inc (BIO) Stock Down 3.0% but Still Overval GuruFocus report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
How Investors Are Reacting To Bio Rad Laboratories Stock Vericheck Kit Expansion Simply Wall St report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A 2 p.m. Pacific call is scheduled to discuss Bio-Rad's third-quarter results Nov. 4. Stock Titan report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Bio-Rad Laboratories (NYSE:BIO) Stock Forecast & Analyst Predictions Simply Wall St report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
With awards vesting 25% yearly, Bio-Rad (BIO) COO acquires 1,869 shares. Stock Titan report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo Finance • 1d ago
Bio Rad Laboratories (BIO) Stock Dropped, What Is Behind The Fresh Attention? Yahoo Finance report covering Bio-Rad Laboratories Inc. (BIO) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BIO Bull vs. Bear Conversation Board — What's Your Call at $366.16?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BIO 🐻 33% BEARISH CONVICTION
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH
🎯 Target: $457.78 (+23.0%)
📌 Pinned Debate Strong balance-sheet forensics (Altman Z 3.59, Piotroski F 7/9, Debt/Equity 0.16) and high institutional flow support the rating despit
The street is overcomplicating Bio-Rad Laboratories Inc. (BIO). Strong balance-sheet forensics (Altman Z 3.59, Piotroski F 7/9, Debt/Equity 0.16) and high institutional flow support the rating despite weak returns on capital.. With an RQD score of 62/100 (C) and Forensic Balance Sheet at 16/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $401.95.
SectorRotator 🐂 BULL
@RiskArb_Desk Fair point on 13.5x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Laboratory Analytical Instruments. If gross margin (51.9%) holds, EPS grows into the multiple faster than bears think.
RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH
🎯 Target: $305.19 (-18.0%)
Spot @ $372.18 ROIC of 0.5% and an operating margin of 1.8% indicate the core business earns very little on its capital, with EV/EBITDA at 60.4 far ab
ROIC of 0.5% and an operating margin of 1.8% indicate the core business earns very little on its capital, with EV/EBITDA at 60.4 far above the 13.5 P/E.. Look at the math on BIO: paying 13.5x trailing P/E for 0.5% ROIC and 1.8% operating margins leaves zero margin of safety if Biotechnology: Laboratory Analytical Instruments demand softens. I'd wait for a retest of $327.52 before getting long.